Abstract: A cover material-equipped patch comprising: a patch; and a cover material, wherein the patch comprises a support layer and a drug reservoir layer which is stacked on one surface of the support layer and which contains a drug and a drug reservoir base agent, the cover material comprises a cover layer and an adhesive layer which is stacked on one surface of the cover layer and which contains an adhesive base agent, the patch and the cover material are arranged in such a manner that the adhesive layer is stacked on another surface of the support layer, and a solubility parameter (SPa) of the drug, a solubility parameter (SPb) of the drug reservoir base agent, and a solubility parameter (SPc) of the adhesive base agent simultaneously satisfy conditions represented by the following formulae (1) to (3): 0?|SPa?SPb|?1.5??(1), 2.0?(SPa?SPc)?2.8??(2), and 1.0?(SPb?SPc)?2.8??(3).

Abstract: Provided is a patch 1 containing a backing layer 2 and a pressure-sensitive adhesive layer 3 formed on the backing layer 2, where the pressure-sensitive adhesive layer 3 contains (i) ropinirole and a metal salt produced by the reaction of a ropinirole acid adduct and a metal ion containing desalting agent in an equivalent mole or less to the acid adduct and (ii) an adhesive base free of a hydroxyl group and a carboxy group.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer is 5 to 13.2% by mass relative to a total mass of the adhesive agent layer.

Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

Abstract: A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer is 5 to 13.2% by mass relative to a total mass of the adhesive agent layer.

Abstract: Provided is a transdermal preparation having low skin irritation as well as a sufficient skin permeability rate of donepezil, which comprises one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof. Also provided are a manufacturing method thereof, and a method for reducing skin irritation of a transdermally absorbable donepezil-containing preparation. An embodiment is a transdermal preparation comprising one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof, and a skin irritation-reducing agent.

Abstract: Provided is a patch 1 containing a backing layer 2 and a pressure-sensitive adhesive layer 3 formed on the backing layer 2, where the pressure-sensitive adhesive layer 3 contains (i) ropinirole and a metal salt produced by the reaction of a ropinirole acid adduct and a metal ion containing desalting agent in an equivalent mole or less to the acid adduct and (ii) an adhesive base free of a hydroxyl group and a carboxy group.

Abstract: Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects.

Abstract: It is intended to provide a transdermal absorption patch which is highly excellent in transdermal absorption properties and long-lasting drug effect even in the case where a drug-effect component contained in the transdermal absorption patch is a basic drug hardly soluble in a pressure-sensitive adhesive base, has a high stability of the drug contained therein with the passage of time and can achieve improvement in the compliance and simplification of the administration method. These problems can be solved by providing a transdermal absorption patch which contains a basic drug having an octanol/water partition coefficient (logarithm) in the free state of 3 or above, a pressure-sensitive adhesive base and a (meth)acrylic copolymer having carboxyl group.